null Ramy Saleh, MD, M.Sc., FRCPC

Investigator, RI-MUHC, Glen site

Cancer Research Program

Assistant Professor, Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University



medical oncology • phase I • clinical trials • GU malignancies • sarcoma

Research Focus

My main research focus is on early-stage clinical trials (phases 1 and 2) and testing new medications in cancer patients for the first time. My goal is to bring cutting-edge medications to metastatic cancer patients and provide them with new and extra treatments in their fight against cancer. In addition, my academic interests include quality improvement in the medical field, with a focus on medical oncology. This involves enhancing work efficiency while increasing patient safety and reducing costs to the healthcare system. For the last ten years I have been heavily involved in creating medical platforms to address those needs and, at the same time, link multiple systems together to reduce the burden on healthcare professionals.

Selected Publications

Click on Pubmed to see my current publications list

  • Park C, Moria F, Saleh RR. Combination of Osimertinib with Concurrent Chemotherapy and Hormonal Therapy for Synchronous NSCLC, Hormone Receptor-Positive Breast Cancer, and Triple-Negative Breast Cancer: Case Report. Case Rep Oncol (2023) 16 (1): 1080–1086.

  • Moria F, Park C, Eigl B, Macfarlane R, Pavic M, Saleh RR. A Real-world Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada. Curr. Oncol. 2023, 30.

  • Cardenas LM, Ghosh S, Finelli A, Wood L, Kollmannsberger C, Basappa N, Graham J, Heng D, Bjarnason G, Soulières D, Bossé D, Castonguay V, Saleh RR, Tanguay S, Bhindi B, Breau RH, Pouliot F, Lalani AA. Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. JCO Glob Oncol. 2023 Sep;9:e2300271.

  • Saleh RR, Scott J, Meti N, Perlon D, Fazelzad R, Ocana A, Amir E. Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. Mol Diagn Ther. 2022 Mar;26(2):153-168.

  • Saleh RR, Nadler MB, Desnoyers A, Meti N, Fazelzad R, Amir E. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. 2021 Aug 28;100:102283.